NCT02966314View on ClinicalTrials.gov

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Idiopathic Angioedema
Interventions
DRUG

Omalizumab

Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.

DRUG

Placebos

Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.

Trial Locations (1)

53792

UW Madison, Madison

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Wisconsin, Madison

OTHER